Clinical Trial Update: "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating aliskiren added to standard therapy in adults with stable heart failure, reporting efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Tekturna (aliskiren)

Snippet

Sponsor: Novartis | Conditions: Heart Failure | Phase 3 | Status: COMPLETED